Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION.

Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, Strasser DS, Delahaye S, Hess P, Vezzali E, Mentzel U, Menard J, Clozel M, Iglarz M.

J Pharmacol Exp Ther. 2019 Jan 8. pii: jpet.118.253864. doi: 10.1124/jpet.118.253864. [Epub ahead of print]

2.

The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat.

Rey M, Kramberg M, Hess P, Morrison K, Ernst R, Haag F, Weber E, Clozel M, Baumann M, Caroff E, Hubler F, Riederer MA, Steiner B.

Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.338.

Supplemental Content

Loading ...
Support Center